Vaginal carcinoma

Vaginal carcinoma (also known as vaginal cancer or cancer of the vagina) is a rare malignant neoplasm arising from the tissues of the vagina. It accounts for approximately 1-2% of all gynecological malignancies. The most common histological type is squamous cell carcinoma, which represents about 80-90% of cases, followed by adenocarcinoma, melanoma, and sarcoma. A historically notable subtype, clear cell adenocarcinoma of the vagina, was linked to in utero exposure to diethylstilbestrol (DES). The disease primarily affects the reproductive system but can spread locally to the bladder, rectum, and pelvic structures, and may metastasize to distant organs including the lungs and liver. Key symptoms include abnormal vaginal bleeding (especially postmenopausal bleeding), watery or blood-tinged vaginal discharge, a palpable mass or lesion in the vagina, pelvic pain, painful urination (dysuria), and constipation. Many early-stage cases may be asymptomatic and detected incidentally during routine gynecological examination or cervical screening. Risk factors include advanced age, human papillomavirus (HPV) infection, prior cervical intraepithelial neoplasia or cervical cancer, a history of hysterectomy, smoking, and immunosuppression. Treatment depends on the stage, location, and histological type of the tumor. For early-stage disease, surgery (including local excision, partial or total vaginectomy, and in some cases radical hysterectomy with lymph node dissection) may be curative. Radiation therapy, often combining external beam radiation with brachytherapy, is the mainstay of treatment for most stages and is frequently used as primary therapy, particularly for more advanced disease. Concurrent chemoradiation with cisplatin-based regimens may be employed for locally advanced tumors. Prognosis varies significantly by stage, with five-year survival rates ranging from approximately 70-80% for stage I disease to less than 20% for stage IV. Due to its rarity, management is often guided by evidence extrapolated from cervical cancer treatment protocols.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Vaginal carcinoma